Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study

Journal of Neural Transmission

Volumn 108, Issue 2, 2001, Pages 215-219

  Negrotti, A ^a   Bizzarri, G ^a   Calzetti, S ^a  

^a Istituto di Neurologia   (Italy)

Author keywords

Parkinson's disease; Selegiline; Symptomatic effect; Withdrawal

Indexed keywords

BROMOCRIPTINE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; SELEGILINE;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MOOD; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREMOR;

AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; SELEGILINE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0034928980     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170089     Document Type: Article

References (6)

1. L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: A short-term, double-blind, and prospective follow-up study
2. Selegiline monotherapy in the treatment of Parkinson's disease
3. Role of selegiline in combination therapy of Parkinson's disease
4. The effect of deprenyl and levodopa on the progression of Parkinson's disease
5. Selegiline delays the onset of disability in de novo parkinsonian patients
6. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease